Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Covid-19 Vaccine Maker Stocks Higher Amid Variant Concerns

11/26/2021 | 12:07pm EST

By Michael Dabaie

Shares of Covid-19 vaccine makers Moderna Inc., Pfizer Inc. and BioNTech SE were higher Friday after South Africa raised alarms about a fast-spreading new variant of the coronavirus.

Moderna shares rose 26% to $345.54 and Pfizer was up 5.5% to $53.67, while American depositary receipts of BioNTech, which collaborates with Pfizer on a vaccine, were 21% higher to $369.11.

Equity markets were broadly lower amid concerns over the variant, with the Dow Jones Industrial Average, Nasdaq and S&P 500 each down more than 2%.

"The scientific, political and economic focus on the Nu variant is well founded despite the limited data," Citi said in commentary on the new variant. "The next two weeks with be critical to determine whether Nu will displace delta in countries with high background rates such as U.K. and Germany."

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

11-26-21 1206ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 4.97% 162.22 Delayed Quote.-37.08%
MODERNA, INC. 7.30% 159.47 Delayed Quote.-37.21%
PFIZER, INC. 1.80% 54.33 Delayed Quote.-7.99%
All news about MODERNA, INC.
01/28Easier to produce COVID vaccine shows promise in trials; nasal spray vaccine booster wo..
RE
01/28SVB Leerink Adjusts Moderna's Price Target to $85 From $86, Maintains Underperform Rati..
MT
01/28Moderna, Pfizer Boosters Provide High Level of Protection Against Omicron, UK Health Se..
MT
01/27Pfizer/BioNTech, Moderna COVID-19 Booster Shots Provide Protection Against Death from O..
MT
01/27Moderna, IAVI Say Clinical Trial of Experimental HIV Vaccine Antigens is Underway
MT
01/27MODERNA : IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Tec..
PU
01/27WALL STREET STOCK EXCHANGE : Are we still in the Goldilocks zone?
01/27MARKETSCREENER'S WORLD PRESS REVIEW : January 27, 2022
01/26Pfizer-BioNTech, Moderna COVID-19 Jabs Shown Safe For Women Undergoing IVF in Study
MT
01/26Moderna Launches Mid-Stage Study of Omicron-Specific Booster Jab
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 17 766 M - -
Net income 2021 11 257 M - -
Net cash 2021 11 938 M - -
P/E ratio 2021 6,00x
Yield 2021 -
Capitalization 64 657 M 64 657 M -
EV / Sales 2021 2,97x
EV / Sales 2022 1,93x
Nbr of Employees 1 300
Free-Float 90,5%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 159,47 $
Average target price 262,47 $
Spread / Average Target 64,6%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-37.21%60 258
LONZA GROUP AG-19.46%48 939
IQVIA HOLDINGS INC.-17.77%44 321
SEAGEN INC.-20.50%22 475
ICON PUBLIC LIMITED COMPANY-17.13%20 892
CELLTRION, INC.-23.74%17 086